The following stories appear in full on today's Vidyya Medical News Service Web site.
Smoking greatly increases the risk of developing a particular type of skin cancer, researchers from the Leiden University Medical Center in the Netherlands, have found. Squamous Cell Carcinoma is already one of the more common skin cancers, normally developing later in life.
For more information: Smoking Can Triple Skin Cancer Risk
The R.W. Johnson Pharmaceutical Research Institute (PRI), a member of the Johnson & Johnson family of companies, submitted its New Drug Application (NDA) for the Ortho Evra(TM) (norelgestromin/ethinyl estradiol) transdermal system, a seven-day contraceptive patch, to the U.S. Food and Drug Administration.
The FDA's standard review period for an NDA is 12 months. If approved,
Ortho Evra would be the world's first prescription transdermal contraceptive.
For more information: Transdermal Method Of Contraception Submitted For FDA Approval
A new brain imaging study from the Institute of Psychiatry shows for the first time that the thalamus, the brain's main sensory filter or 'hub', is smaller than normal from the earliest stages of schizophrenia. The findings, published in the American Journal of Psychiatry in January, may explain why people with schizophrenia experience confusion during their illness.
For more information: New MRI Technique Shows Thalamus Is Smaller Than Normal From The Earliest Stages Of Schizophrenia
Novartis has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Starlix® (nateglinide), the first in a new class of oral antidiabetic drugs that restores early insulin secretion, a fundamental defect in type 2 diabetes. It is indicated for use as both monotherapy and in combination with metformin, another oral antidiabetic medication, in patients whose blood glucose (sugar) is not controlled by diet and exercise. In the United States, more than 13 million people have type 2 diabetes and the incidence is expected to increase.
For more information: US FDA approves Novartis' Starlix
Study results published in the current issue ofThe Lancet (vol 356, issue 9248) show that Exelon® (rivastigmine) alleviates behavioral disturbances in patients with dementia with Lewy bodies (DLB). DLB (also referred to as the Lewy body variant of Alzheimer's disease) is the second most common form of dementia1 and is characterized by severe behavioral disturbances.
For more information: Rivastigmine Alleviates Behavioral Disturbances In Patients With Dementia With Lewy Bodies
Today's Vidyya articles are:
As always, we hope you enjoy the issue.